Ibustrin (Indobufen)

Indobufen reversibly inhibits platelet cyclooxygenase‑1, which reduces the synthesis of thromboxane A2, a potent promoter of platelet aggregation. By lowering thromboxane A2 levels, the drug diminishes platelet activation and the formation of arterial clots.

The dosage of Ibustrin is individualized by the prescribing healthcare professional based on the patient’s clinical condition, risk factors, and concomitant therapies. The prescriber determines the appropriate strength, frequency, and duration of treatment.

Safety data for indobufen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Ibustrin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ibustrin (indobufen) differs from aspirin and clopidogrel by providing reversible cyclooxygenase inhibition, which may result in a distinct safety profile, especially regarding gastrointestinal tolerance. Choice of antiplatelet therapy depends on patient‑specific factors, drug interactions, and physician judgment.

Ibustrin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in high‑heat or humid environments.

Ibustrin is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include severe or uncontrolled bleeding, thrombocytopenia (low platelet count), and hepatic dysfunction. Patients should be monitored for signs of excessive bleeding, unusual bruising, or liver‑related symptoms and seek medical attention promptly if they occur.

Ibustrin is contraindicated in individuals with known hypersensitivity to indobufen or any component of the formulation, active major bleeding, or severe liver disease. Caution is also advised for patients on multiple anticoagulants or with a high bleeding risk.